The production of amyloid-β (Aβ) is the key factor driving pathogenesis in Alzheimer's disease (AD).
Introduction
Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia as a consequence of synaptic failure (1,2). The amyloid hypothesis maintains that the pivotal event in AD is the production of toxic amyloid-β (Aβ) peptides following the proteolytic cleavage of the amyloid precursor protein (APP) (3) . In animal models intracerebral injections of Aβ peptides caused synapse damage and impaired memory formation (4, 5) . Neurodegeneration is not directly proportional to concentrations of Aβ; rather that it is dependent upon numerous factors including the state of Aβ aggregation and specific Aβ conformations. Perhaps the key to understanding the amyloid hypothesis is the realization that there exist conformational forms of disease-relevant Aβ, while other conformations are less toxic or even biologically inert. Therefore, we sought to identify factors that specifically affected the release of toxic forms of Aβ.
Chinese hamster ovary (CHO) cells stably transfected with cDNA encoding the human (APP)751, known as 7PA2 cells, have been extensively used as they release soluble Aβ (6, 7) that have similar properties to the soluble Aβ species found within the brains of AD patients (8) (9) (10) (11) .
The loss of synaptic proteins such as synaptophysin from the brain is indicative of synapse degeneration and provided a good correlate of the degree of dementia in AD (12) (13) (14) . Consequently, the loss of synaptic proteins from cultured primary neurons incubated with Aβ provides a useful in vitro model in which to investigate AD-related synapse damage (15) . Synapse density in cultured neurons was measured by quantification of the amounts of synaptophysin and cysteine string protein (CSP) (15) . Picomolar concentrations of soluble Aβ caused the loss of synaptophysin and CSP from cultured neurons (15) and impaired memory formation in animal models (10, 16) .
Although many studies implicate cholesterol concentrations as a major factor that regulates Aβ production, as reviewed by Chang and colleagues (17), the effects of cholesterol depletion on Aβ production remain controversial. While initial studies demonstrated that cholesterol depletion reduced the production of Aβ (18) , another study reported it increased Aβ concentrations (19) . However, the conventional cholesterol synthesis inhibitors (3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) used to deplete cells of cholesterol also block the production of isoprenoids, which also affect Aβ concentrations (20, 21) .
Consequently it is not clear whether the effects of these drugs on Aβ concentrations are mediated by their effects upon cholesterol, or upon isoprenoid concentrations. In addition, previous studies have not differentiated the effects of cholesterol depletion upon the type of Aβ produced (toxic/non-toxic).
Abbreviations -Alzheimer's Disease (AD), amyloid-β (Aβ), amyloid precursor protein (APP), arachidonyl trifluoromethyl ketone (AACOCF3), Chinese hamster ovary (CHO), cholesterol ester hydrolase (CEH) conditioned media (CM), cholesteryl N-(2-dimethylaminoethyl) carbamate (c-carbamate), cysteine string protein (CSP), diethylumbelliferyl phosphate (DEUP), endoplasmic reticulum (ER), 1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,Ntrimethyl)-hexanolamine (Hexa-PAF), methyl arachidonyl fluorophosphonate (MAFP), phospholipase A2 (PLA2), platelet-activating 3 Here we show that treatment of 7PA2 cells with squalestatin, a squalene synthetase inhibitor that inhibits cholesterol synthesis without affecting the production of isoprenoids (22) , reduced the release of synaptotoxic Aβ; conditioned media (CM) from these cells did not cause synapse degeneration when added to cultured neurons. Surprisingly, squalestatin had only a small affect upon the total concentrations of Aβ42 in CM, rather it changed the ratio of Aβ oligomers to Aβ monomers. Treatment reduced concentrations of the synaptotoxic Aβ oligomers and increased concentrations of neuroprotective Aβ monomers (23) . This study also identified other drugs that affected the type of Aβ released; the release of soluble Aβ oligomers was reduced by treating 7PA2 cells with either phospholipase A2 (PLA2) inhibitors, platelet-activating factor (PAF) antagonists or cholesterol ester hydrolase (CEH) inhibitors. The observation that PAF activated CEHs, resulting in increased cholesterol concentrations within the endoplasmic reticulum (ER), led to the hypothesis that PAF-induced activation of CEH releases cholesterol that consequently affected the production of Aβ oligomers.
Methods

Culture of 7PA2 cells -Chinese hamster ovary (CHO) cells stably transfected with cDNA encoding
APP751 (referred to as 7PA2 cells) originated from Professor E Koo's laboratory (National University of Singapore) were grown in Dulbecco's minimum essential medium supplemented with 10% foetal calf serum as described (6) . For experiments 7PA2 cells were grown in 6 well plates until 80% confluent.
Culture media was replaced with neurobasal medium containing B27 components (Invitrogen) ± test compounds including squalestatin (a gift from GlaxoSmithKline), squalene, arachidonyl trifluoromethyl ketone (AACOCF3), platelet-activating factor (PAF), 1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho- was removed by centrifugation (20 minutes as 16000 x g). Both 7PA2-CM and cell extracts were centrifuged at 100,000 x g for 4 hours at 4 0 C and passed through a 50 kDa filter (Sartorius). The CM from treated 7PA2 cells was then desalted (3 kDa filter, Sartorius to remove any residual drugs) and the retained material (> 3 kDa) diluted to its original volume. CM and cell extracts from non-transfected CHO cells (CHO-CM) were used as controls. 7PA2-CM containing Aβ monomers were prepared by filtration of 2 mls 7PA2-CM through a 10 kDa filter (Sartorius). Oligomer preparations were the 7PA2-CM retained by the 10 kDa filter diluted back to the original volume (2 mls).
Soluble brain extracts -
Were prepared from the temporal lobes of patients with a clinical, and pathologically-confirmed, diagnosis of Alzheimer's disease using methods as described (10) . Briefly, brain tissue was cut into pieces of approximately 100 mg and added to 2 ml tubes containing lysing matrix D beads (Q-Bio). PBS was added so that there was the equivalent of 100 mg brain tissue/ml. The tubes were shaken for 10 minutes (Disruptor genie, Scientific Instruments) to homogenize tissue. This process was performed 3 times before tubes were centrifuged at 16,000 x g for 10 minutes to remove cell debris. Soluble material was prepared by passage through a 50 kDa filter (Sartorius) (16,000 x g for 30 minutes) followed by desalting, retention by a 3 kDa filter (Sartorius) to eliminate bioactive small molecules and drugs. The retained material was collected (preparation contains peptides with molecular weights between 3 and 50 kDa) and stored at -80 o C.
Western
Blotting -For immunoblot analysis, 7PA2-CM/monomer or oligomer preparations were concentrated from 2000 to 100 µls using a 3 kDa filter (Sartorius). 10 µl of sample were mixed with an equal volume of in 0.5% NP-40, 5 mM CHAPS, 50 mM Tris, pH 7.4 and separated by electrophoresis on 15% polyacrylamide gels. Proteins were transferred onto a Hybond-P polyvinylidene fluoride membrane by semi-dry blotting and blocked using 10% milk powder. Aβ was detected by incubation with mAb 6E10 (Covance), biotinylated anti-mouse IgG, extravidin-peroxidase and enhanced chemiluminescence.
Aβ immunodepletions -
To deplete preparations of Aβ they were incubated with 1 μg/ml mAb 4G8
(reactive with amino acids 17-24 of Aβ, Covance) or 1 μg/ml mAb LN27 (reactive with amino acids 45 to 53 of APP, (mock depletion)) and incubated on rollers for 2 hours. Protein G microbeads were added (10 µl/ml) (Sigma) for 30 minutes and protein G bound-antibody complexes removed by centrifugation (1000 x g for 5 minutes).
Primary neuronal cultures -
Cortical neurons were isolated from the brains of mouse embryos (day 15.5) after mechanical dissociation and cell sieving as described (24 
Isolation of Endoplasmic Reticulum -(ER) membranes -ER membranes were isolated from 7PA2
cells using an ER preparation kit (Sigma) following the manufacturer's instructions. Briefly, homogenised cell extracts were separated on a discontinuous density gradient (Opitiprep) and membranes containing ER components were identified with mAb reactive to the ER marker Grp 78 (Stressgen Biotechnology) (25) .
ER membranes were pre-treated ± drugs for 30 minutes and incubated with PAF for 1 hour.
Synaptophysin ELISA -
The amount of synaptophysin in neurons were measured by ELISA (26) .
Maxisorb immunoplates (Nunc) were coated with an anti-synaptophysin mouse mAb (MAB368-Millipore) was used as a capture antibody and bound synaptophysin was detected using rabbit polyclonal antisynaptophysin (Abcam) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and finally 1 mg/ml 4-nitrophenol phosphate (Sigma). Absorbance was measured on a microplate reader at 405 nm. Samples were expressed as "units synaptophysin" where 100 units was defined as the amount of synaptophysin in control neurons.
CSP ELISA -
Maxisorb immunoplates were coated with a monoclonal antibody (mAb) to CSP ((sc-136468) Santa Cruz) and blocked with 5% milk powder. Samples were added and bound CSP was detected using rabbit polyclonal anti-CSP ((sc-33154) Santa Cruz) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate solution. Absorbance was measured at 405 nm. Samples were expressed as "units CSP" where 100 units was the amount of CSP in control neurons. x g for 10 mins at 4 o C). The pellet was washed twice with ice-cold acetone, suspended in a buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% SDS and sonicated.
2.11. Aβ42 ELISA -Nunc Maxisorb immunoplates were coated with an anti-Aβ mAb (4G8 -epitope 17-24, Covance) in carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-tween and samples were applied for 1 hour. The detection antibody was an Aβ42 selective rabbit mAb BA3-9 (Covance) followed by biotinylated anti-rabbit IgG and extravidin alkaline phosphatase (Sigma) and 1 mg/ml 4-nitrophenol phosphate solution. Optical density was read in a spectrophotometer at 405 nm.
2.12.
Aβ40 ELISA -Maxisorb immunoplates were coated with mAb 4G8 (epitope 17-24) and blocked with 5% milk powder in PBS-tween. Samples were applied and Aβ40 was detected with rabbit polyclonal PC-149 (Merck) followed by biotinylated anti-rabbit IgG and extravidin alkaline phosphatase. Total Aβ was visualised by addition of 4-nitrophenol phosphate and optical density was read in a spectrophotometer at 405 nm. Table 1 ). The effects of 7PA2-CM on neuronal synaptophysin levels was removed by immunodepletion with mAb 4G8, but was unaffected by mock-depletion ( Figure 1D ) indicating that Aβ was the synaptotoxic component. As the 4G8 mAb used in these depletions reacts with an epitope common to several APP breakdown fragments including Aβ40 and Aβ42 and others (28) the current study does not identify the precise toxic entities. The effects of 7PA2-CM were than compared to that of soluble brain extracts derived from an Alzheimer's patient (15) . 7PA2-CM and soluble brain extracts containing similar concentrations of Aβ42 caused dose-dependent reductions in synaptophysin ( Figure 1E ) and CSP ( Figure   1F ).
Statistical Analysis -
Squalestatin reduced the amounts of synaptotoxic Aβ in CM -
The effects of cholesterol depletion on the production of Aβ were examined after collecting CM from 7PA2 cells treated with 500 nM squalestatin, a squalene synthetase inhibitor (29) . Squalestatin reduced the concentrations of cholesterol in 7PA2 cells and the concentrations of Aβ42 and Aβ40 in CM, without affecting cell survival (Table 2 ). CM from 7PA2 cells treated with 500 nM squalestatin did not cause synapse damage (Figures 2A & B) . This effect of squalestatin was dose-dependent ( Figure 2C ). The effects of squalestatin upon 7PA2 cells were reversed by the addition of 5 μM squalene; it increased cellular cholesterol concentrations and concentrations of Aβ40 and Aβ42 within CM (Table 2) . Furthermore, CM from 7PA2 cells treated with a combination of 500 nM squalestatin and 5 μM squalene caused more synapse damage than CM from 7PA2 cells treated with 500 nM squalestatin alone ( Figure 2D ). The addition of 5 μM squalene alone did not 8 affect the concentrations of cholesterol in 7PA2 cells, nor did it affect concentrations of Aβ40 and Aβ42 found in CM. oligomers ( Figure 5C ) and increase in Aβ42 monomers ( Figure 5D ). 3.7. PAF caused the release of cholesterol from cholesterol esters -A prior study had shown that PAF receptors were concentrated in membranes which also contained Grp78, a marker of the endoplasmic reticulum (ER) (32) . The addition of PAF to ER membranes caused dose-dependent increases in cholesterol concentrations ( Figure 7A ) and reductions in concentrations of cholesterol esters ( Figure 7B ). There was a significant inverse correlation between concentrations of cholesterol and cholesterol esters in ER membranes incubated with PAF (0.125 to 1μM) ( Figure 7C ). The PAF-induced increase in cholesterol concentrations in these membranes was not affected by pre-treatment with 500 nM squalestatin indicating that PAF did not stimulate cholesterol synthesis ( Figure 7D ). The concentrations of cholesterol within cell membranes is partly controlled by the cholesterol ester cycle (33) and membrane cholesterol concentrations can be increased following activation of CEHs, enzymes that release cholesterol from cholesterol esters (34) . Pre-treatment of ER membranes with 2 CEH inhibitors (diethylumbelliferyl phosphate (DEUP)) (35) and cholesteryl N-(2-dimethylaminoethyl) carbamate (36) inhibited both the PAF-induced increase in 10 cholesterol concentrations ( Figure 7E ) and the reduction in cholesterol ester concentrations ( Figure 7F ).
Squalestatin reduced the release of Aβ42 oligomers -
We concluded that PAF altered cholesterol concentrations via its effects upon CEHs. 
CEH inhibitors reduced the release of synaptotoxic Aβ -
CEH inhibitors did not have a direct effect upon Aβ42 oligomers -These results raised the possibility that drugs may interact directly with Aβ oligomers within the CM causing them to dissociate into
monomers. This hypothesis was tested by incubating Aβ preparations with 500 nM squalestatin, 1 μM Hexa-PAF or 20 μM DEUP at 37 o C for 3 days. An immunoblot showed that there were no significant differences in the amounts of Aβ oligomers and monomers between control and treated preparations ( Figure   9 ). In another experiment Aβ oligomer preparations (containing 10 nM Aβ42) were incubated with 500 nM squalestatin, 1 μM Hexa-PAF or 20 μM DEUP at 37 o C for 3 days. When these preparations were passed through a 10 kDa filter, monomeric forms of Aβ42 were not detected indicating that these drugs had not caused the dissociation of Aβ42 oligomers.
CEH inhibitors reduced cell-associated Aβ42 oligomers -
The possibility that the drugs tested simply affected the release, rather than the production of Aβ was examined by measuring Aβ in cell extracts from treated 7PA2 cells. The concentrations of Aβ42 oligomers in 7PA2 cell extracts were significantly reduced by treatment with 500 nM squalestatin, 1 µM AACOCF3, 1 µM MAFP, 1 µM Hexa-PAF, 1 µM ginkgolide B, 1 µM DEUP or 20 µM cholesteryl N-(2-dimethylaminoethyl) carbamate (Table 4) . Treatment with these drugs also increased the amounts of cell-associated Aβ42 monomers. Figure 10D ). We note that in addition to Aβ40 and Aβ42 there are likely to be other APP fragments in the monomer preparations and that these may contribute to the activity seen here.
CM from treated 7PA2 cells protected neurons against
Discussion
Although many studies have examined the factors that affect Aβ production this is the first study that we are aware of that differentiated between toxic and non-toxic forms of Aβ. The release of biologically active forms of Aβ by 7PA2 cells was examined using synapse damage in cultured neurons as a model. The synapse damage caused by 7PA2-CM was comparable to that caused by soluble brain extracts from AD patients when standardized on their Aβ42 content. In addition, the synapse damage caused by both 7PA2-CM and brain extracts (15) Our observation that squalestatin caused only small differences in the production of Aβ40 and Aβ42 was in contrast to prior reports of the effects of other cholesterol synthesis inhibitors. This may be due to using 12 squalestatin, a more specific cholesterol synthesis inhibitor that does not affect isoprenoid function (22) , rather than conventional "statins" used in other reports. Furthermore, the reduction in cellular cholesterol concentrations in these studies was mild when compared to other studies (19, 37) . The key observation, that CM from squalestatin-treated cells contained Aβ42 but did not cause synapse damage, showed that measuring concentrations of Aβ alone was a poor indicator of biological activity. That squalestatin selectively affected the production of soluble Aβ oligomers, thought to be major causes of synapse damage in AD (10, 16, 38) , is consistent with a report that reduced cholesterol synthesis did not affect Aβ production but did extend lifespan in a mouse model of AD (39) . Cholesterol affects the formation and function of lipid rafts (40, 41) in which APP and many of the enzymes involved in the generation of Aβ are found (42) (43) (44) . Consequently, it seems likely that the squalestatin-induced reduction in cholesterol concentrations would affect the processing of APP to Aβ oligomers.
Cholesterol concentrations within the ER were increased after activation of cPLA2 (25) . This enzyme affects tubule formation and consequently intracellular trafficking of proteins (31) In contrast to squalestatin, neither cPLA2 inhibitors, nor PAF antagonists, had a significant effect on 7PA2 cellular cholesterol concentrations, and their effects upon Aβ production were not reversed by squalene indicating that they did not affect cholesterol synthesis. However, it could be argued that Aβ production might be affected by small changes in cholesterol concentrations in specific organelles which would not be seen in total cell membrane extracts. PAF receptors were concentrated in the ER and PAF increased 
Conclusions
In conclusion these results indicate that in 7PA2 cells the production of synaptotoxic and neuroprotective forms of Aβ can be modified by pharmacological manipulation. More specifically, the Aβ monomer:oligomer ratio was sensitive to drugs that altered cholesterol concentrations in cell membranes.
Furthermore this study demonstrates the need to understand the biological activity of the forms of Aβ measured.
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